Progesterone or progestin as menopausal ovarian hormone therapy

This recent paper confirms the positive benefits of oral Micronised Progesterone (OMP), which is the natural progesterone I use in my prescriptions. Medroxyprogesterone acetate (MPA) is the usual progestin used in most synthetic HRT. It has a deleterious effect, as shown below.
Curr Opin Endocrinol Diabetes Obes. 2015 Dec;22(6):495-501. doi: 10.1097/MED.0000000000000205.

Progesterone or progestin as menopausal ovarian hormone therapy: recent physiology-based clinical evidence.

Author information

  • 1Endocrinology and Metabolism, Centre for Menstrual Cycle and Ovulation Research (CeMCOR), Department of Medicine, School of Population and Public Health, University of British Columbia, Vancouver Coastal Health Research Institute, Vancouver, Canada.

Abstract

PURPOSE OF REVIEW:

Provide evidence-based recent data on oral micronized progesterone (OMP) and progestins in menopausal hormonal therapy (MHT).

RECENT FINDINGS:

Medroxyprogesterone acetate (MPA) increases breast cancer acting through the glucocorticoid receptor; progestins in MHT increase thrombosis more than oral estrogens; MPA, but not OMP or other progestins, increase monocyte cell endothelium adhesion; MPA and estradiol (E2)/MPA have negative brain effects, whereas E2/progesterone (P4) has neuroregenerative brain effects. The ‘window of opportunity’ cardiovascular disease hypothesis is not supported by a randomized controlled trial showing that transdermal estradiol with sequential OMP in early menopause does not prevent increased carotid intimal media thickness; P4 in the cardiac electrical system opposes E2 effects and prevents sudden death/long QT syndrome; transdermal estradiol/OMP does not increase venous thromboembolism in observational data. P4 decreases breast cell proliferation and improves prognosis through P4 receptor alteration of estrogen receptor α genetic effects; OMP with conjugated equine estrogen (CEE)/estrogen (E)/E2 does not increase breast cancer in two prospective cohorts, one population-based. Endometrial cancer is increased in MHT of CEE/E/E2+cyclic OMP at 200 mg/day.

SUMMARY:

New data show CEE/E/E2+MPA/P mechanisms for negative breast cancer, venous thromboembolism, cardiovascular system, and brain effects. OMP/P4 counterbalances CEE/E/E2-related negative effects on breast cancer and long QT syndrome. OMP effectively treats vasomotor symptoms and sleep disturbances, and could safely be used alone for symptomatic menopause.

About Dr Colin Holloway

Gp interested in natural hormone treatment for men and women of all ages

Posted on June 9, 2016, in Uncategorized. Bookmark the permalink. Leave a comment.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: